SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: EX-99.1 2 v169191_ex99-1.htm
[EX-99.1 2 v169191_ex99-1.htm]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)
[v169191_ex99-1.htm 2 EX-99.1]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: v169191_ex99-1.htm 2 EX-99.1
[v169191_ex99-1.htm 2 EX-99.1]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] DEF 14A: (Original Filing)
[Payment of Filing Fee (Check the appropriate box): x No fee required. o Fee computed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11.]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] DEF 14A: (Original Filing)
[Payment of Filing Fee (Check the appropriate box): x No fee required. o Feemputed on table below per Exchange Act Rules 14a-6(i)(4) and 0-11. 1) Title of each class of securities to which transaction applies: 2)gregate number of securities to which transaction applies: 3) 4) Proposed maximumgregate value of transaction:]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[Skystar Bio-Pharmaceutical Acquires Exclusive Aquaculture Vaccine Technology and Provides Operational Update on Facility Development New Vaccine Technology to Address Company-Estimated $150 Million Market Opportunity Veterinary Vaccine Facility Launch Extended to First Quarter of 2010 to Accommodate New Aquaculture Vaccine Line XI'AN, CHINA, December 9 , 2009 — Skystar Bio-Pharmaceutical Company Skystar will manufacture its aquaculture vaccine in its new 51,000]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: Skystar Bio-Pharmaceutical Acquires Exclusive Aquaculture Vaccine Technology and
[Skystar Bio-Pharmaceutical Acquires Exclusive Aquaculture Vaccine Technology and Provides Operational Update on Facility Development New Vaccine Technology to Address Company-Estimated $150 Million Market Opportunity Veterinary Vaccine Facility Launch Extended to First Quarter of 2010 to Accommodate New Aquaculture Vaccine Line XI'AN, CHINA, December 9 , 2009 — Skystar Bio-Pharmaceutical Company Skystar will manufacture its aquaculture vaccine in its new 51,000]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: (Original Filing)
[Skystar Bio-Pharmaceutical Acquires Exclusive Aquaculture Vaccine Technology and Provides Operational Update on Facility Development New Vaccine Technology todressmpany-Estimated $150 Million Market Opportunity Veterinary Vaccine Facility Launch Extended to First Quarter of 2010 to Accommodate New Aquaculture Vaccine Line XI'AN, CHINA, December 9 , 2009ystar Bio-Pharmaceuticalmpanyystar will manufacture its aquaculture vaccine in its new 51,000 square]
SKBI [SKYSTAR BIO-PHARMACEUTICAL] 8-K: Skystar Bio-Pharmaceutical Acquires Exclusive Aquaculture Vaccine Technology and
[Skystar Bio-Pharmaceutical Acquires Exclusive Aquaculture Vaccine Technology and Provides Operational Update on Facility Development New Vaccine Technology todressmpany-Estimated $150 Million Market Opportunity Veterinary Vaccine Facility Launch Extended to First Quarter of 2010 to Accommodate New Aquaculture Vaccine Line XI'AN, CHINA, December 9 , 2009ystar Bio-Pharmaceuticalmpanyystar will manufacture its aquaculture vaccine in its new 51,000 square]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] 8-K: (Original Filing)
[EX-99.1 2 v167082_ex99-1.htm]
